Patent Law Weblog
recent posts
- Retired Judges File Amicus Brief in Support of Judge Newman
- Hikma v. Amarin at the Supreme Court: The Parties’ Opening Briefs
- Teva Pharmaceuticals International v. Eli Lilly & Co. (Fed. Cir. 2026)
- USPTO Extends Artificial Intelligence Search Automated Pilot Program (ASAP!)
- USPTO Announces That It Has Turned the Corner on Unexamined Application Backlog
about
Month: April 2007
-
By Donald Zuhn — SinoBiomed announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 7,101,556, which is directed to fusion proteins comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1) and the production of anti-malarial vaccines using such proteins. In its release,…
-
By Christopher P. Singer — The USPTO released this pre-OG notice regarding its electronic priority document exchange program (PDX) implemented in conjunction with the European Patent Office (EPO). This program is intended to benefit applicants that have filed an application with the U.S. or European Patent Offices (a "priority document"), and subsequently wish…
-
By Mark Chael — On Friday, April 27, 2007 at 9:00 am, the Seton Hall University School of Law (SHU Law) will hold a press conference to announce the establishment of the Center for Health & Pharmaceutical Law. The mission of the new Center will be "to address the evolving legal and public…
-
By Christopher P. Singer — AstraZeneca PLC announced on Monday that it plans to acquire MedImmune Inc. in a deal estimated to be worth about $15 billion. AstraZeneca expects that this acquisition, in combination with its earlier acquisition of Cambridge Antibody Technology (CAT) will place it among the top biologics companies in the…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Breckenridge Pharmaceutical, Inc. v. Cornerstone Biopharma, Inc. et. al.8:07-cv-01004; filed April 19, 2007 in the District Court of Maryland Declaratory judgment of…
-
By Donald Zuhn — Last Thursday, Novartis AG announced that it had signed an exclusive license with Antisoma PLC for the worldwide rights to the cancer therapeutic AS1404. AS1404 is a member of a class of compounds known as small molecule vascular disrupting agents (VDAs). VDAs, which selectively disrupt established blood vessels supporting…
-
April 27, 2007 – Patent Claim Construction Workshop (Law Seminars International) – Atlanta, GA May 6-9, 2007 – BIO International Convention – Boston, MA June 26-28, 2007 – Euro-Biotech Forum 2007 – Paris, France
-
"Biotech/Pharma" Top 50 (+1) By Donald Zuhn — On Monday, the Intellectual Property Owners Association (IPO) released its annual list of the top 300 organizations receiving U.S. patents in 2006. The IPO’s release of the list comes three months after the U.S. Patent & Trademark Office (PTO) announced that it would no longer…
-
By Robert Dailey — Novozymes and Genencor (Danisco) reached a settlement involving Genencor’s infringement of U.S. Patent No. 6,867,031. The patent covers alpha-amylases useful in the manufacture of fuel-grade ethanol. As previously reported by Patent Docs, Novozymes had prevailed over Genencor in an infringement trial and subsequently proved that Genencor’s infringement had been…
-
By Kevin E. Noonan — On Tuesday, the U.S. Department of Justice (DOJ) and Federal Trade Commission (FTC) released an extensive (218 page) report on their analysis of the relationship between antitrust law and patent law (see "Antitrust Enforcement and Intellectual Property Rights: Promoting Innovation and Competition"). And in what may come as…
Patent Docs 